Be Prepared, FDA to Hand Down Approval Decision for ACelRx Next Month
Research - AcelRx (ACRX) will receive an approval decision form the US FDA next month for Zalviso. Read more, and understand our point of view, here.
Premium: Read NowResearch
Two Technical Setups with Quality Fundamental Backstories
Research - Two technical trade ideas, both names PropThink has followed for some time, with quality, fundamental backstories.
Premium: Read Now
Intercept Isn’t The Only Way to Play Rare Liver Diseases
Research - Intercept (ICPT) jumped to the top of many watchlists when a drug for liver diseases showed success in a P2 trial. Here's another, cheaper idea.
Read Now
Orexigen Breaks Seven Dollars With PDUFA One Day Out
Research - Orexigen Therapeutics (OREX) broke above $7 in the Tuesday trading session, a day before the FDA issues a decision on the New Drug Application for NB32 (Contrave) as … Continue Reading
Premium: Read Now
The Retrophin Catch-22
Research - Retrophin management has pinned shareholders and potential investors between a rock and a hard spot, but there's reason to be optimistic.
Premium: Read NowFinally. An Encouraging Week in Biotech
Research - The sector-tracking iShares NASDAQ biotechnology ETF (IBB) took out some major levels of resistance in the Thursday trading session, catching the attention of traders in the … Continue Reading
Read Now
Antibiotic Incentives Loom, Cubist Still Positioned to Benefit
Research - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read Now